Chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) antibodies (such as trastuzumab), anti-VEGFR2 antibodies (such as ramucirumab), and immune checkpoint inhibitors are standard therapies for unresectable or recurrent gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.